They propose based on rodent and monkey studies that this kind of molecule, when administered at high enough doses, may result in weight loss comparable to the weight loss seen with drugs that include GLP-1 as a target, and without the tolerability issues like nausea and vomiting that often come with the approved treatments, according to a peer-reviewed draft paper published this week
Triple-receptor agonists or triagonists in development target GLP-1, GIP, and glucagon receptors
29 For your ROI, this is a disaster
My Experience: Having worked in the Jander lab a previous summer, I was expecting an experience like what I already knew, of carrying out experiments and letting my mentor decide what I would do for his and my projects
doi: 10.1093/ajcn/nqy175
However, there are situations when your body's glutamine needs exceed its capacity to manufacture it